TriSalus announces $22M private placement, Q1 revenue up 42% to $9.2M

TriSalus Life Sciences, Inc.

2025-Q1 EPS reported -$0.39 revenue$9,167,000

Private placement of 5.5M shares at $4.00/share raises ~$22M gross; led by Nantahala Capital, Broadfin Holdings. Expected close May 2, 2025.
Preliminary Q1 2025 revenue ~$9.2M (solely from TriNav Infusion System), +42% YoY.
Exchange offer for Series A Preferred Stock: each share exchanged for common at formula based on $10.00 liquidation preference plus accrued dividends through Aug 2027 divided by $4.00.
Special meeting to vote on amendment allowing company to call Preferred Stock for conversion and eliminate July 2027 conversion price reset.

item 1.01 item 2.02 item 3.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.